Isis Pharmaceuticals Inc. (ISIS) announced after the close Wednesday that data from the Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy were presented at the 65th American Academy of Neurology Annual Meeting.
Isis Pharmaceuticals has been rising since the open of trade Thursday and is now up 1.60 at $19.44 on above average volume. The stock has climbed above a 2-week range and has set a new high for the year.
For comments and feedback: editorial@rttnews.com